LOS ANGELES, CA / ACCESSWIRE / November 16, 2017 / Processa Pharmaceuticals, Inc. (OTC PINK: PCSA), an emerging company focused on the clinical development of drugs for the treatment of high unmet medical need conditions, announced today that it will be presenting at the 10th annual LD Micro Main Event on Tuesday, December 5th at 1:00 pm PST, at the Luxe Hotel Sunset Boulevard in Los Angeles, CA. David Young, PharmD, PhD, CEO of Processa, will be presenting and meeting investors along with Patrick Lin, Chief Business & Strategy Officer.
The Processa Team helped take Questcor Pharmaceuticals from a $15M Market Cap company in 2007 to a $5.6B company in 2014 and has a proven track record in drug development with over 30 FDA approvals and 100 FDA meetings. They are presently developing a product for 2 indications, potential maximum sales of $1.0B - $2.7B and $400M - $870M, and the proof-of-concept clinical efficacy data already existing for this product in both indications.
The LD Micro Main Event is the largest independent conference for small/micro-cap companies and will feature 250 names presenting to an audience of over 1,000 attendees. In addition, there will be a variety of speakers/panelists discussing topics of interest to investors and issuers, along with coordinate evening events.
News Compliments of Accesswire
About PROCESSA
Processa Pharmaceuticals is an emerging biotech company focused on the clinical development of drug products that are intended to improve the survival and/or the quality of life of patients who have a high unmet medical need condition. Within this group of products, Processa is presently developing treatments for two conditions with no approved treatment or standard of care as well as searching for additional clinical stage assets to acquire and develop.
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into several influential conferences annually.
In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector.
For those interested in attending, please contact David Scher at [email protected] or visit www.ldmicro.com/events for more information.
Contact:
Name: Patrick LinPhone: 925-402-4275
Address: 7380 Coca Cola Drive, Suite 106, Hanover, MD 21076
Email: [email protected]
SOURCE: Processa Pharmaceuticals, Inc.